Clinical trials: Prostate Cancer (Diagnosis), open to volunteers
Prostate Cancer (Diagnosis)
Investigation of an Intelligent Centre-adaptive Multi-modal Fusion Framework (Cad- MMFF) to Overcome Unnecessary Prostate Biopsies and Optimize MRI Utilization
This study aims to investigate a novel Centre-Adaptive Multi-Modal Fusion Framework (Cad-MMFF) that integrates clinical, ultrasound, and MRI data to improve the detection of clinically significant prostate cancer (csPCa), reduce…
- Trial name
- NCT07760857
- Where
- 2 sites in Hong Kong
- Volunteers
- 400 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer (Diagnosis), ACP3
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
This study aims to evaluate the feasibility, safety, and diagnostic performance of 68Ga-XMFH01, a novel ACP3-targeted dual-modality PET and fluorescence imaging probe, for preoperative PET/CT imaging and intraoperative…
- Conditions
- Prostate Cancer (Diagnosis), ACP3, PET / CT
- Trial name
- NCT07885423
- Testing
- 68Ga-XMFH01 PET/CT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Prostate Cancer (Diagnosis)
Hugo™ Robotic Assisted Surgery (RAS) System in Prostatectomy Patients Treated in an ASC Setting
A Single-center Study of Robotic Prostatectomy Surgeries Performed using the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in an Ambulatory Surgical Center Setting
- Trial name
- NCT07875192
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Central Ohio Urology Group
Prostate Cancer (Diagnosis), Prostate Cancer Stage IV
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
In patients with prostate cancer (PC), cardiovascular disease (CVD) causes significant morbidity and is the second leading cause of death.
- Conditions
- Prostate Cancer (Diagnosis), Prostate Cancer Stage IV, CV Risk
- Trial name
- NCT07223385
- Testing
- Cardio-Oncology Referral, Notification to PCP/General Cardiologist
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cedars-Sinai Medical Center
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis)
Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making
Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.
- Trial name
- NCT07856017
- Where
- 4 sites in China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Prostate Cancer (Diagnosis), Prostatic Neoplasms
Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)
Current prostate cancer diagnosis relies on MRI-targeted biopsy combined with a 12-core systematic biopsy. The systematic component is a major driver of overdiagnosis of insignificant cancer and biopsy-related morbidity, and…
- Trial name
- FLASH (NCT07846592)
- Testing
- Ex vivo real-time fluorescence microscopy of prostate biopsy cores (EndoScell system, model MES-1000P)
- Volunteers
- 450 people
- Sponsor
- Shanghai East Hospital
Prostate Cancer (Diagnosis)
CascadeDiagnose Prostate MRI
This multicenter clinical study is evaluating CascadeDiagnose Prostate MRI, an artificial-intelligence software tool that analyzes standard prostate MRI scans-T2-weighted, diffusion-weighted, and ADC images-to help radiologists…
- Trial name
- NCT07844304
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Prostate Cancer (Diagnosis)
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT
Prostate cancer is one of the most common malignancies in men. Currently, due to the limited diagnostic accuracy of existing imaging tests, there is a risk of missed diagnosis or unnecessary prostate biopsy.
- Trial name
- NCT07690306
- Where
- 6 sites in United States, China
- Volunteers
- 1,500 people
- Sponsor
- Xiangya Hospital of Central South University
Prostate Cancer (Diagnosis)
Advanced Diffusion Magnetic reSonance Prostate Imaging for Reducing Extraneous Biopsies (ASPIRE) - Calibration Component (Multi-centre Scanner Calibration) and Validation Component (Multi-centre Validation)
In 2019 the UK National Institute for Health and Care Excellence (NICE) updated its guidelines to recommend Magnetic Resonance Imaging (MRI) for all patients prior to biopsy as it permits the targeted sampling of suspicious…
- Trial name
- ASPIRE MS (NCT07808528)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- University College, London
Prostate Cancer, Prostate Cancer (Diagnosis)
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma
- Trial name
- LUTACT (NCT07054346)
- Testing
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Thomas Hope
Prostate Cancer, Urology
A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth
This prospective observational study will enroll men referred for prostate biopsy due to elevated PSA and/or abnormal digital rectal examination, with or without pre-biopsy MRI.
- Conditions
- Prostate Cancer, Urology, Prostate Cancer (Diagnosis)
- Trial name
- PROSTest_STRAT (NCT07454603)
- Testing
- PROSTEST
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Wren Laboratories LLC
Prostate Cancer (Diagnosis)
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
- Trial name
- NCT07615101
- Testing
- 68-Ga-NYM032
- Where
- 2 sites in China
- Volunteers
- 365 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI…
- Trial name
- ECETEP (NCT07766122)
- Testing
- Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Prostate Cancer (Diagnosis), Prostate Biopsy
TENS During Transperineal Prostate Biopsy
Transperineal prostate biopsy is a safe and effective method of diagnosing prostate cancer. When performed under local anaesthesia in an outpatient setting, it can cause significant pain, particularly during the periprostatic…
- Conditions
- Prostate Cancer (Diagnosis), Prostate Biopsy, Pain, Procedural
- Trial name
- TENS 2 (NCT07578324)
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- Poland
- Volunteers
- 140 people
- Sponsor
- Medical University of Gdansk
Prostate Cancer (Diagnosis)
miRNA Panel for PCa Diagnosis
This is a single-center, prospective diagnostic accuracy trial conducted at Renji Hospital, Shanghai Jiao Tong University School of Medicine, led by a team of urology and molecular medicine researchers.
- Trial name
- NCT07755592
- Testing
- Serum microRNA panel detection for prostate lesion differentiation
- Where
- China
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Prostate Cancer, Prostatic Neoplasms/Diagnosis
VALIDATION OF FUSION CEMEP SCORE FOR OMITTING SYSTEMATIC PROSTATE BIOPSY
This study aims to prospectively validate the Fusion CEMEP score to assess the safety and efficacy of omitting systematic prostate biopsy in patients undergoing multiparametric magnetic resonance imaging-targeted biopsy.
- Trial name
- FUSION-CEMEP (NCT07753356)
- Testing
- FUSION CEMEP SCORE STRATEGY
- Where
- Argentina
- Volunteers
- 150 people
- Sponsor
- Marcelo Ruben Oliva
Prostate Cancer (Diagnosis)
Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the degree of serious disease.
- Trial name
- NCT07144228
- Testing
- HeLP TM
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Duke University
Thyroid Pathology, Head and Neck Cancer (H&N)
FAPI PET Imaging - An Exploratory Study
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions…
- Conditions
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis
- Trial name
- FAPIPET (NCT07705074)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 5 sites in Switzerland
- Volunteers
- 770 people
- Sponsor
- Martin Huellner
Prostate Cancer (Diagnosis), Transperineal Cryoablation
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)
The purpose of this study is to evaluate the feasibility, safety, and potential protective benefit of Barrigel, a hyaluronic acid-based rectal spacer, in patients undergoing prostate cryoablation for localized or recurrent…
- Trial name
- NCT07567027
- Testing
- Barrigel Injectable Gel, Cryoablation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Lung Cancer Diagnosis, Colorectal Cancer (Diagnosis)
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program.
- Conditions
- Lung Cancer Diagnosis, Colorectal Cancer (Diagnosis), Prostate Cancer Diagnosis, Breast Cancer Diagnosis
- Trial name
- NCT06559059
- Testing
- National TeleOncology
- Where
- 5 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- NYU Langone Health